More recently, the Columbia group has evaluated medications in a more complicated human laboratory design that models both withdrawal and relapse. Regular cannabis users were maintained on each medication condition for 7 inpatient days. Each medication phase was separated by an outpatient washout phase. During the first three inpatient days, placebo cannabis was available for self-administration (withdrawal). For the next 4 days, active cannabis was available for self-administration. Participants paid for self-administered cannabis using study earnings.
